In recent days, Novovita received a few million dollars in Series A financing from an undisclosed backer. The funds will be used to accelerate the development and research of its products and building the new production center.
Novovita has its own R&D center and technology platform, including biomaterials medical device technology platform and medical device combined with a slow release controlled technology platform.
Novovita's 3 types of aseptic implanted medical device products have completed clinical trials in 2017 and entered the State Food and Drug Administration's registration phase in 2018.